Top Abstract Purchase Related
Home
>
Node
>
Subnode

Review of Clinical Studies on Combination Therapy of 5α-Reductase Inhibitors and Α1-Blockers in Patients with Benign Prostatic Hyperplasia

Spivak, L.G.; Lokshin, K.L.; Vinarov, A.Z.

Urologiia 2015(4): 125-133

2015

ISSN/ISBN: 1728-2985
PMID: 26665780
Document Number: 683725
The review presents the results of studies on combination therapy of 5α-reductase inhibitors and α-blockers in patients with benign prostatic hyperplasia (BPH). These data demonstrate a significant advantage of the combination therapy versus monotherapy in terms of quality of life and subjective symptoms as well as the safety, better results in the prevention of BPH progression and acute urinary retention, and reduced need for surgery.

Document emailed within 1 workday
Secure & encrypted payments

Djavan, B.; McConnell, J. 1996: The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia Wiener Medizinische Wochenschrift 146(8): 165-168
Sun, Z.Y.; Tu, Z.H. 1998: A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia Methods and Findings in Experimental and Clinical Pharmacology 20(4): 283-287
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
Savage, S.J..; Spungen, A.M..; Galea, G.; Britanico, J.; Vapnek, J.M.. 1998: Combination medical therapy for symptomatic benign prostatic hyperplasia Canadian Journal of Urology 5(3): 578-584
Takayama, T.; Arakawa, I.; Kakihara, H.; Tachibana, K.; Ozono, S. 2012: Pharmacoeconomic evaluation of combination therapy with dutasteride and α1 blocker for treatment of benign prostatic hyperplasia in Japan Hinyokika Kiyo. Acta Urologica Japonica 58(2): 61-69
2003: 5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked MMW Fortschritte der Medizin 145(27-28): 58-59
Lowenthal, D.T.; Flannery, M.; Mader, S.L.; Nelson, R.P. 1998: Benign prostatic hyperplasia: maximizing treatment with alpha blockers Geriatrics 53(Suppl 2): S4-28
Effert, P.; Ackermann, R. 1992: Clinical manifestations and indications for therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 31(3): 135-141
Denti, L.; Pasolini, G.; Cortellini, P.; Sanfelici, L.; Benedetti, R.; Cecchetti, A.; Ferretti, S.; Banchini, A.; Ablondi, F.; Valenti, G. 1999: Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH) Journal of Endocrinological Investigation 22(10 Suppl): 70-71
Schulman, C.C.; Zlotta, A.R. 1994: Transurethral needle ablation (TUNA): histopathological, radiological and clinical studies of a new office procedure for treatment of benign prostatic hyperplasia Progress in Clinical and Biological Research 386: 479-486
Nishimoto, K. 1990: Clinical evaluation of isometric detrusor pressure in patients with benign prostatic hyperplasia Hinyokika Kiyo. Acta Urologica Japonica 36(1): 19-26
Suzuki, K.; Ichinose, Y.; Hashimoto, K.; Matsumoto, K.; Suzuki, T.; Imai, K.; Yamanaka, H. 1990: Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography Hinyokika Kiyo. Acta Urologica Japonica 36(5): 557-560
Mazo, E.B.; Dmitriev, D.G. 2001: Clinical effect of the drug "Prostamol-Uno" in patients with benign prostatic hyperplasia and chronic prostatitis Urologiia 5: 38-41
Sivkov, A.V.; Egorov, A.A.; Romikh, V.V.; Surikov, V.N. 2002: Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia Urologiia 2002(5 Suppl): 13-22
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Goldfarb, B.; Bartkiw, T.; Trachtenberg, J. 1995: Microwave therapy of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 431-439
Ekman, P. 1992: Drug therapy of benign prostatic hyperplasia Lakartidningen 89(45): 3803-3804
Fan, G.-R.; Yang, E.-G.; Gao, S.-Z.; Wang, Z.-P. 2019: Genetic polymorphisms in benign prostatic hyperplasia: Progress in studies Zhonghua Nan Ke Xue 25(10): 934-938
Deng, Z.-X.; Ji, L.-X.; Zhang, Y.-R.; Li, C.-d.; Cai, J.; Jiang, H.-H. 2018: Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia : a short-term clinical observation Zhonghua Nan Ke Xue 24(1): 72-77